Skip to main
ACIU

AC Immune (ACIU) Stock Forecast & Price Target

AC Immune (ACIU) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AC Immune is a biopharmaceutical company that is primarily focused on developing precision medicine treatments for neurodegenerative diseases. They have a diverse pipeline of programs targeting misfolded proteins, including ACI-24, Crenezumab, ACI-35, Semorinemab, and ACI-7104. The company recently reported positive financial results for the first quarter of 2026, with a decrease in R&D expenses and a significant increase in total cash resources. They have upcoming catalysts, including the release of data for the ACI-24 vaccine in Alzheimer's disease and the potential exercise of an option by Takeda for ACI-24, which could provide a substantial source of revenue. Additionally, they are exploring partnerships for their ongoing clinical and discovery programs, which could further bolster their financial position. Overall, AC Immune's innovative approach to targeting neurodegenerative diseases and their strong financial standing make the company a promising investment opportunity.

Bears say

AC Immune is currently heavily reliant on its pipeline of misfolded protein targeting therapies, which face technical and biological risks as they are based on educated guesses of toxic species structure and lack significant evidence of cognitive benefit in Parkinson's Disease (PD). Additionally, its AD program appears to be more de-risked than PD due to the established link between plaque clearance and cognitive benefit, as well as a better-established readout through PET scans compared to the semi-quantitative measurement used for aSyn aggregates. The company's future success is therefore uncertain and dependent on the success of its pipeline.

AC Immune (ACIU) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AC Immune (ACIU) Forecast

Analysts have given AC Immune (ACIU) a Strong Buy based on their latest research and market trends.

According to 1 analysts, AC Immune (ACIU) has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AC Immune (ACIU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.